RASSF3

Across TCGA pan-cancer cohorts, RASSF3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RASSF3 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RASSF3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RASSF3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where RASSF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.899	0.485	.002	24	view →
LUAD	OS	Tertile	III,IV	0.354	1.000	.018	11	view →
PDAC	OS	Tertile	III,IV	1.000	0.460	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RASSF3–HNSC (DFS)

Open the HNSC breakdown →